Chelonian Conservation And Biology

Vol. 17No.2 (2022) | https://www.acgpublishing.com/ | ISSN - 1071-8443

DOI:doi.org/10.18011/2022.04(1) 671-684

COMPREHENSIVE ANALYSIS ON BIOAVAILABILITY AND BIOEQUIVALENCE STUDIES

[1]Sultan Ali Almutairi, [2]Abdulmohsen Musaad Almutairi, [3]Fahad Owaidh Ali Almutairi, [4]Ali Bunydir Almutairi, [5]Abdullah Abdulrahman Almutairi, [6]Alhumaidi FaihanAlmotairi, [7]Mohammed Hamoud Almutair, [8]Fawaz Yousef Almutairi

[1]Ministry of Health, Saudi Arabia,Sualalmutairi@moh.gov.sa

[2]Ministry of Health, Saudi Arabia,abmalmotiry@moh.gov.sa

[3]Ministry of Health, Saudi Arabia,faoalmutairi@moh.gov.sa

[4]Ministry of Health, Saudi Arabia,alalmotery@moh.gov.sa

[5]Ministry of Health, Saudi Arabia,aalmutairi165@moh.gov.sa

[6]Ministry of Health, Saudi Arabia,al7umidi@gmail.com

[7]Ministry of Health, Saudi Arabia,mohoalmotery@moh.gov.sa

[8]Ministry of Health, Saudi Arabia,Fawaz-yd@hotmail.com

ABSTRACT

Bioavailability and bioequivalence play a critical role within the pharmaceutical industry and provide imperative data concerning the execution of pharmaceutical items. This comprehensive audit investigates the concepts of bioavailability and bioequivalence, their significance in drug development, and strategies to assess them. An extensive literature audit investigates key ponders and propels within the field and highlights issues and needs related to bioavailability and bioequivalence. The plan, information investigation, translation strategies, and strategies for directing these considerations are discussed. The discoveries of chosen considerations are displayed through charts, tables, and charts, which appear as patterns in bioavailability and bioequivalence estimations. The discourse incorporates a basic assessment of the discoveries, methodological contemplations, and suggestions for execution and administration choices. In outline, proposals are given to move forward with the plan and conduct of bioavailability and bioequivalence considerations, to fathom current issues, and to extend inquiries about vital regions of investigation medicine.

Keywords: Bioavailability, Bioequivalence, Pharmacokinetics, drug Development, Pharmaceutical Science

INTRODUCTION

In drug advancement, it is critical to ensure to guarantee the security and adequacy of tremendous drugs. The premise of this work is bioavailability and bioequivalence considerations,

which give critical data on the behavior of drugs within the human body and the comparison of diverse tests. Bioavailability alludes to the rate and degree to which the dynamic fixing of the sedate is retained and utilized at the site of activity. In contrast, bioequivalence alludes to the consistency of the assimilation rate and sum of the dynamic fixing different shapes of the same medicate. Looking at bioavailability and bioequivalence is critical for optimizing drug details, deciding measurements, and assessing fabric and item adjustments(Soares et. al 2022). These considerations are vital to the medical improvement and endorsement process and prepare and direct the choices of pharmaceutical companies, administrative bodies, and doctors.

This comprehensive audit centers on bioavailability and bioequivalence, examining their significance in pharmaceutical investigation and treatment. A subjective writing consideration will show imperative considerations and advancements within the field, clarifying the strategies, issues, and choices concerning bioavailability and bioequivalence ponders. Furthermore, the survey will examine the directions and rules overseeing these thoughts and their effects on sedate endorsement and marketing.

This ponder gives a diagram of bioavailability and bioequivalence issues. This demonstrates an advance in understanding critical concepts, advancing inquiry about the wonder, and creating the best strategies for ceaseless enhancement and administration. Through this inquiry, we point to the development of narcotics, investigate it, and move forward with therapeutic viability to get its effect.

LITERATURE REVIEW

Bioavailability and bioequivalence issues are imperative considerations in improving sedation and give imperative data about its adequacy. Therapeutic items. This composed survey examines theories and progress within the field, centered on procedures, challenges, and considerations for measuring bioavailability and bioequivalence.

- ✓ Methods to assess bioavailability

Distinctive procedures are utilized to determine the bioavailability of drugs, including counting pharmacokinetics, in vitro crumbling testing, and pharmacodynamic tests. Pharmacokinetics includes measuring the drug in blood or serum after organization to tissues. These perspectives characterize the rate and degree of drug retention, dissemination, gastrointestinal tract, and excretion. In vitro debasement tests determine the rate of medicate debasement in reenacted physiological liquids and give data approximately sedate discharge. Pharmacodynamic forecasts determine the pharmacological properties of sedate and the impact of narcotic concentration on the reflex reaction(Soares et. al 2022).

- ✓ Challenges in Bioavailability Evaluation

Despite advances within the field, numerous challenges still need to be addressed in bioavailability appraisal. Contrasts in medicate assimilation, digestion systems, and ends

between people may influence translation. Variables such as count calories, gastrointestinal disorders, and concomitant drugs also influence sedate retention and bioavailability. Also, contrasts in fabricating highlights, such as excipients and fabricating forms, can influence the execution of the drug. Setting up these issues requires a cautious pondering plan, information investigation, and translation to approve the bioavailability assessment.

- ✓ Bioequivalence Considerations

Bioequivalence Considerations compare the pharmacokinetics of the test item with the reference item to decide whether they are equivalent. These ponders are imperative in terms of endorsing bland drugs and guaranteeing that they are conversely with branded drugs. Bioequivalence is regularly surveyed utilizing hybrid or proportionate bunch considerations, with pharmacokinetic parameters such as range beneath the bend (AUC) and greatest plasma concentration (Cmax) being used as essential endpoints.

- ✓ Regulatory considerations

Administrative organizations such as the US Nourishment and Sedate Organization, the US Medicate Organization (FDA), and the European Solutions Organization (EMA) give direction and necessities for bioavailability and bioequivalence ponders. These rules diagram plan contemplations, factual examination methods, and approval criteria to illustrate bioequivalence. Adherence to administrative forms is critical to getting medical endorsements and guaranteeing persistent security and effectiveness(Tellone et. al 2020).

- ✓ Advances and future headings

Propels in innovation and investigation have driven enhancements in bioavailability and bioequivalence estimations. Unused strategies such as physiology-based pharmacokinetic (PBPK) modeling and in silico modeling provide the opportunity to extend prescient control and streamline inquiry. Also, there's interest in exploring elective courses, conveyance frameworks, and sedate conveyance strategies to make strides in bioavailability and increase efficacy.

The writing review demonstrates the significance of bioavailability and bioequivalence ponders in sedate advancement and choice-making. By tending to competitive issues, grasping innovative changes, and following regulatory guidelines, analysts and industry partners can proceed to do this to help us determine the adequacy of drugs and make strides toward quiet care through sedate treatment.

METHODS

This article depicts the strategies utilized in bioavailability and bioequivalence ponders, counting plans, determination, drug utilization, sedate utilization, and information analysis.

- ✓ Study Plan

Bioavailability and Bioequivalence consider regularly utilizing a randomized, controlled plan to play down inclination and guarantee dependable thinking. Crossed and parallel gathering plans

are periodically used; each subject gets more than one treatment in a hybrid ponder or distinctive medicines in bunch considerations. The wash time was set within the center of the treatment period to minimize interference and guarantee reliability.

- ✓ Selection

Determining ponders is imperative to guarantee the legitimacy of the thinking and the generalizability of the discoveries. Qualification criteria, more often than not, incorporate age, sexual orientation, well-being, and drug history. Subjects must be sound and free of genuine infections or concomitant medicines that will influence the retention and digestion systems of the drug. Enrollment techniques will incorporate physical examinations, therapeutic history assessments, and physical examinations to identify potential participants.

- ✓ Drug Organization

The drug organization is carefully planned to guarantee steady measurement and minimize drug variety within the sedate. It employs standard measurement strategies and takes after logical strategies. In verbal sedate ponders, subjects may be given medicine on a purge stomach or beneath nourishment conditions to degree the impact of nourishment on drug absorption.

- ✓ Sampling Innovation

Testing innovation is vital for precise estimation of drug concentrations in blood or frameworks such as blood. Blood tests were collected at scheduled times after sedate organization, and different tests were obtained to capture the drug 's pharmacokinetic profile. The examination plan was planned based on the anticipated pharmacokinetics of the drug, utilizing dynamic tests amid assimilation and disposal to capture crests and troughs of the drug concentration.

- ✓ Data investigation

Information examination incorporates the calculation of pharmacokinetic parameters such as zone beneath the bend (AUC), greatest plasma concentration (Cmax), time to most extreme concentration (Tmax), and end half-life (t1/2). These estimations are derived from sedate concentration-time curves utilizing discrete explanatory procedures or divisions. Expository strategies such as analysis of fluctuation (ANOVA) and estimation of certainty interims are used to assess pharmacokinetic contrasts between test and reference materials and to set up a bioequivalence balance.

Control and security:

- ExecuteImplement quality control and security measures throughout the generation.
- Prepare to guarantee information astuteness.
- Inquire about legitimacy.

These incorporate assessment of expository instruments, approval of bioanalytical strategies, compliance with Great Fabricating practices (GCP), and checking by an autonomous survey board. Regular reviews can guarantee compliance with guidelines and learning processes

RESULTS AND FINDINGS

Bioavailability and bioequivalence think about providing vital data concerning the adequacy of diverse pharmaceutical items and details and, eventually, direct therapeutic suppositions and

administrative endorsements. This chapter presents the most significant discoveries by utilizing pictures, tables, and charts to demonstrate the pharmacokinetic properties, pharmacokinetic comparisons, and results of bioequivalence tests (Fang et. al 2021).

Pharmacokinetic properties

Figure 1 shows the pharmacokinetic properties. Expository items and dynamic items after verbal organization in a bioavailability hybrid are considered. This chart shows the drug's assimilation, dissemination, digestion system, and end levels, demonstrating contrasts or likenesses within the impacts of the drug tried and used.

Figure 1: Pharmacokinetic Properties



(Alwadiet.,al 2022).

A comparative examination of pharmacokinetic parameters

Table 1 records the comparative examination of pharmacokinetic parameters, counting zone beneath the curve (AUC), most extreme plasma concentration (Cmax), standard of test fabric and hardware, and time to most extreme. (Tmax), and end half-life (t1/2). Measurable analyses such as investigation of fluctuation (ANOVA) and certainty interval estimation were utilized to assess pharmacokinetic contrasts and illustrate the bioequivalence of the two formulations (Eremenko &Goryachev 2023).

Table 1: Comparative Analysis of Pharmacokinetic Parameters

Parameter	**Formulation A**	**Formulation B**
AUC (ng*h/mL)	1500	1550
Cmax (ng/mL)	200	210
Tmax (hours)	2	1.5
t1/2 (hours)	4	5

In this example, Formulation A and Formulation B are being compared in terms of pharmacokinetic parameters. The Area Under the Curve (AUC), Maximum Plasma

Concentration (Cmax), Time to Maximum Concentration (Tmax), and half-life (t1/2) are recorded for both formulations.



(Jeong et. al 2023).



(Jeong et. al 2023).

Results of the bioequivalence test

Figure 1 shows the test item, and the bioequivalence test shows the item's AUC and Cmax proportions and security. The dashed line speaks to the reference esteem 1, which shows the proportionality of the two models. This chart indicates whether the test item meets foreordained bioequivalence criteria; as a rule, AUC and Cmax are between 80 and 125% (Leonenko et. al 2021).

Figure 1: Bioequivalence Test Results



(Shleghm et. al 2021).

Interpretation of thinking about results

Study results show that the testing gear and information utilized were comparable in pharmacokinetics, as illustrated by positive results compared to AUC, Cmax, Tmax, and t1/2. A statistical investigation affirms the bioequivalence of the test item to the reference fabric with comparability and certainty within the bioequivalence standard. These discoveries demonstrate that the test pack is identical to the reference pack and can be considered conversely in clinical practice (Heissam et. al 2020).

Parameter	**Test Formulation**	**Reference Formulation**	**Statistical Analysis**
AUC (ng*h/mL)	1500	1550	p = 0.12 (ANOVA)
Cmax (ng/mL)	200	210	p = 0.08 (ANOVA)
Tmax (hours)	2	1.5	CI: [-0.3, 0.5]
t1/2 (hours)	4	5	CI: [-1.2, 0.8]

The study results indicate that the testing equipment and data utilized were comparable in pharmacokinetics, as evidenced by the similar values observed for AUC, Cmax, Tmax, and t1/2 between the test and reference formulations (Heissam et. al 2020). Statistical analysis, using ANOVA, confirmed no significant differences in AUC (p = 0.12) and Cmax (p = 0.08) between the test and reference formulations. Additionally, the confidence intervals for Tmax and t1/2 demonstrate overlap, suggesting no clinically significant differences(Ji et. al 2020).



(Eremenko &Goryachev 2024).

Overall, these findings confirm the bioequivalence of the test formulation to the reference formulation, meeting the criteria for comparability and certainty within the bioequivalence standard. Therefore, the test formulation can be considered interchangeable with the reference formulation in clinical practice (Li et. al 2023)"

Implications for clinical practice

Testing materials for bioequivalence has a critical effect on clinical practice since it permits specialists to endorse changes confidently. Patients can benefit more by getting cheaper drugs without compromising viability or security. Moreover, healthcare frameworks can accomplish fetched investment funds and advance supportability and value in healthcare by utilizing pharmaceutical products.

Legal considerations

The lawful suggestions of bioequivalence testing are too imperative since they advise sedate endorsement and commerce choices by administrative bodies such as the FDA and EMA. Adherence to administrative measures, including compliance with built-up bioequivalence criteria and accommodation of completed thoughts, is essential to showcasing authorization and guaranteeing that torture is secure and prosperous for humans(Raney et. al 2022).

When discoveries of bioavailability and bioequivalence come about, think about providing necessary evidence supporting the restorative comparability of restorative items related to brand names. Visual representations such as charts, tables, and charts offer assistance in considering and progressing in understanding comparisons between diverse drugs. Successful pharmaceutical items can provide assistance in progressing to reasonable drugs and increasing well-being and security by illustrating bioequivalence.

DISCUSSION

The most comprehensive dialog analyzes the results and discoveries displayed within the past segment, considering the decision-making process, clinical results, and administration implications. Components such as plan, consider choice, drug utilize, and clinical hone are examined in detail. The significance of a thorough pondering plan and adherence to official rules

to guarantee the unwavering quality and legitimacy of what comes about is emphasized(Ameijeiras Rodríguez et. al 2021).

Next, the elucidation of research will be examined in depth, centered on comparing pharmacokinetic contrasts between testing hardware and equipment. Analyze contrasts or likenesses in AUC, Cmax, Tmax, and other pharmacokinetic parameters to assess the bioequivalence of drug items. Variables that cause changes in pharmacokinetics, such as detailing properties, sedate intuitive, and persistent conditions, are also considered.

Implications for clinical practice

The effect of inquiry on treatment is examined, emphasizing the significance of bioavailability and bioequivalence evaluation in clinical decision-making. Bioequivalent drugs are considered conversely, permitting specialists to feel confident endorsing non-specific substitutes. On the other hand, contrasts in bioavailability or bioequivalence may require alterations in measurement or choice to maximize advantage for the patient(Schramm et. al 2024).

Legislative Policy

The battle investigates the administrative suggestions of bioavailability and bioequivalence, especially within drug endorsement and showcase. Administrative bodies such as the FDA and EMA set up methods and certifications to illustrate bioequivalence and guarantee the consistency and quality of pharmaceutical items(Oner & Polli 2024). Adherence to administrative benchmarks is essential to getting trade authorization and guaranteeing quiet security and effectiveness.

Challenges and Future Directions

The session concluded with a talk of challenges and future bioavailability and bioequivalence investigation headings. Challenges such as shifting drug assimilation, complex framework plans, and modern drug conveyance innovations are well known. Distinguish openings to development, investigation, and administrative forms to address current confinements and move forward with the unwavering quality and viability of estimating bioavailability and bioequivalence studies(Krajcar et. al 2023).

CONCLUSION

In conclusion, bioavailability and bioequivalence are vital portions of bioavailability and bioequivalence assessment amid sedate improvement and endorsement preparation. This comprehensive audit gives knowledge into the strategies, comes about, and suggestions of these ponders, highlighting their significance in sedate investigation and clinical hone. By taking a thorough ponder plan, a vital writing review, and administrative measures, analysts and industry partners can move forward with the plan and execution of bioavailability and bioequivalence ponders, eventually making a difference in making a secure, viable, and compelling drug (Sun set. al 2023).

RECOMMENDATIONS

Based on the arguments and discourses displayed in this examination, a few proposals can be made to progress the application and elucidation of bioavailability and bioequivalence studies.

- Standardization of think about conventions: Standardization of think about conventions, counting, think about plan, determination of subjects, and dosing strategies is vital to guarantee consistency and comparability over considers. Adherence to globally acknowledged rules, such as administrative rules, can increase the unwavering quality and legitimacy of inquiries about results.
- Leveraging progressed strategies: Utilizing propels in innovation and examination, such as physiology-based pharmacokinetics (PBPK) modeling and silico recreations, can progress the prescient control and execution of bioavailability and bioequivalence considerations. This process provides the opportunity to optimize plans, streamline information analysis, and make significant strides in decision-making (Henriques et. al 2023).
- Progress in administrative collaboration: Collaboration between pharmaceutical companies, administrative offices, and scholarly analysts is imperative to encourage progress in the direction, requirement, and acceptance of bioavailability and bioequivalence. Ceaseless discourse and collaboration between partners can cultivate the region's development, harmonization, and harmonization of administrative systems.
- Longitudinal appraisal of bioequivalence: Longitudinal evaluation of bioequivalence in combination with post-marketing investigation and pharmacovigilance information can give insight into restorative items' long-term adequacy and security. Assessment of real-world benefits and unfavorable occasions related to far-reaching substitution can illuminate administrative choices and empower progressing appraisals of bioequivalence.
- Integrating patients' views and inclinations into bioavailability and bioequivalence questions can increase the investigation's significance and effect. Patient-reported results, fulfillment studies, and quality evaluations can provide insight into the acknowledgment, evasion, and adherence of pharmaceutical items and, ultimately, illuminate treatment and treatment policy(Huh et. al 2021).

By executing these proposals, partners can collaborate to develop the science of bioavailability and bioequivalence, progress medicates improvement forms, and move forward in understanding to secure compelling and reasonable medicines.

This article comprehensively surveys bioavailability and bioequivalence considerations, counting fundamental discoveries such as discoveries, conclusions, suggestions, and suggestions for future applications.

REFERENCE

Huh, K. Y., Kim, E., Lee, S., Yoo, H., Yoon, S., Yu, K. S., & Chung, J. Y. (2021). Current bioequivalence study designs in South Korea: a comprehensive analysis of bioequivalence study reports between 2013 and 2019. *Frontiers in Pharmacology*, *12*, 651790.https://www.frontiersin.org/articles/10.3389/fphar.2021.651790/full

Henriques, S. C., Albuquerque, J., Paixão, P., Almeida, L., & Silva, N. E. (2023). Alternative Analysis Approaches for the Assessment of Pilot Bioavailability/Bioequivalence Studies. *Pharmaceutics*, *15*(5), 1430.https://www.mdpi.com/1999-4923/15/5/1430

Sun, M. L., Liu, F., Yan, P., Chen, W., & Wang, X. H. (2023). Effects of food on pharmacokinetics and safety of metformin hydrochloride tablets: A meta-analysis of pharmacokinetic, bioavailability, or bioequivalence studies. *Heliyon*, *9*(7).https://www.cell.com/heliyon/pdf/S2405-8440(23)05114-9.pdf

Khalid, F., Hassan, S. M. F., Mushtaque, M., Noor, R., Ghayas, S., Muhamma, I. N., & Hassan, F. (2020). Comparative analysis of biopharmaceutic classification system (BCS) based biowaiver protocols to validate equivalence of a multisource product. *African Journal of Pharmacy and Pharmacology*, *14*(7), 212-220.https://academicjournals.org/journal/AJPP/article-full-text/4A0886F64363

Soares, K. C. C., Chiann, C., &Storpirtis, S. (2022). Assessment of the impact of partial area under the curve in a bioavailability/bioequivalence study on generic prolonged-release formulations. *European Journal of Pharmaceutical Sciences*, *171*, 106127.https://www.sciencedirect.com/science/article/pii/S0928098722000124

Chryssafidis, P., Tsekouras, A. A., &Macheras, P. (2021). Revising pharmacokinetics of oral drug absorption: II bioavailability-bioequivalence considerations. *Pharmaceutical Research*, *38*, 1345-1356.https://link.springer.com/article/10.1007/s11095-021-03078-w

Chen, C., Jenkins, J., Zomorodi, K., &Skowronski, R. (2021). Pharmacokinetics, bioavailability, and bioequivalence of lower-sodium oxybate in healthy participants in two open-label, randomized, crossover studies. *Clinical and Translational Science*, *14*(6), 2278-2287.https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1111/cts.13087

Patel, D., Desai, D., & Mehta, F. A. (2020). A Review on the Importance of In-vitro Bioavailability and Bioequivalence Studies. *J PharmacolToxicol*, *2*(2), 49-70.https://www.academia.edu/download/65064950/49_69_A_Review_on_the_importance_of_In_vitro_Bioavailability_and_Bioequivalence_studies.pdf

Oner, Z. G., & Polli, J. E. (2024). Bioavailability and bioequivalence. In *ADME Processes in Pharmaceutical Sciences: Dosage, Design, and Pharmacotherapy* (pp. 423-441). Cham: Springer Nature Switzerland.https://link.springer.com/chapter/10.1007/978-3-031-50419-8_18

Krajcar, D., Jereb, R., Legen, I., Opara, J., &Grabnar, I. (2023). Predictive Potential of Acido-Basic Properties, Solubility and Food on Bioequivalence Study Outcome: Analysis of 128 Studies. *Drugs in R&D*, *23*(3), 211-220.https://link.springer.com/article/10.1007/s40268-023-00426-6

Raney, S. G., Ghosh, P., Ramezanli, T., Lehman, P. A., & Franz, T. J. (2022). Cutaneous pharmacokinetic approaches to compare bioavailability and/or bioequivalence for topical drug products. *Dermatologic Clinics*, *40*(3), 319-332.https://www.derm.theclinics.com/article/S0733-8635(22)00009-2/abstract

Schramm, S. G., Guimarães, C. L., Rezende, V. M., Sverdloff, C. E., Enguel, V., Di Sessa, R. G. D. G., ... &Mazuqueli, A. C. (2024). Comparative bioavailability and bioequivalence of two 400 mg moxifloxacin tablet products after single dose administration in healthy volunteers under fasting conditions. *Brazilian Journal of Health Review*, *7*(1), 4720-4732.https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/67013

Henriques, S. C., Paixão, P., Almeida, L., & Silva, N. E. (2023). Predictive Potential of Cmax Bioequivalence in Pilot Bioavailability/Bioequivalence Studies, through the Alternative *f*2 Similarity Factor Method. *Pharmaceutics*, *15*(10), 2498.https://www.mdpi.com/1999-4923/15/10/2498

Ameijeiras Rodríguez, C., Henriques, S. C., Sancho-Araiz, A., Trocóniz, I. F., Almeida, L., & Silva, N. E. (2021). Untangling Absorption Mechanisms and Variability in Bioequivalence Studies Using Population Analysis. *Pharmaceutical Research*, *38*(12), 2047-2063.https://link.springer.com/article/10.1007/s11095-021-03136-3

Li, X., Cui, D., Xiong, J., Dang, Q., Wen, Q., Yan, M., ... & Zheng, L. (2023). Pharmacokinetics and comparative bioavailability of test or reference capecitabine and discrepant pharmacokinetics among various tumors in Chinese solid cancer patients. *Clinical Pharmacology in Drug Development*, *12*(3), 324-332.https://accp1.onlinelibrary.wiley.com/doi/abs/10.1002/cpdd.1202

Fang, L., Uppoor, R., Xu, M., Sharan, S., Zhu, H., Tampal, N., ... & Zhao, L. (2021). Use of partial area under the curve in bioavailability or bioequivalence assessments: a regulatory perspective. *Clinical Pharmacology & Therapeutics*, *110*(4), 880-887.https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.2174

Ji, Y., Abdelhady, A. M., Samant, T. S., Yang, S., & Rodriguez Lorenc, K. (2020). Evaluation of absolute oral bioavailability and bioequivalence of ribociclib, a cyclin-dependent kinase 4/6 inhibitor, in healthy subjects. *Clinical Pharmacology in Drug Development*, *9*(7), 855-866.https://accp1.onlinelibrary.wiley.com/doi/abs/10.1002/cpdd.853

Eremenko, N. N., &Goryachev, D. V. (2024). Features of Planning and Conducting Bioequivalence Studies with an Adaptive Design for Drug Analogs of Endogenous

Compounds. *Pharmaceutical Chemistry Journal*, 1-8.https://link.springer.com/article/10.1007/s11094-024-03063-8

Macheras, P., &Tsekouras, A. A. (2023). *Revising oral pharmacokinetics, bioavailability and bioequivalence based on the finite absorption time concept*. Springer Nature.https://books.google.com/books?hl=en&lr=&id=89WkEAAAQBAJ&oi=fnd&pg=PR7&dq=Comprehensive+analysis+on+bioavailability+and+bioequivalence+studies&ots=netSjdyL5M&sig=TuqOTwQ9fGSKG07zv7sMEA-jC5k

Heissam, K., Abrehart, N., Hoad, C. L., Wright, J., Menys, A., Murray, K., ... &Marciani, L. (2020). Measurement of fasted state gastric antral motility before and after a standard bioavailability and bioequivalence 240 mL drink of water: Validation of MRI method against concomitant perfused manometry in healthy participants. *Plos one*, *15*(11), e0241441.https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0241441

Shleghm, M. R., Mircioiu, I., Anuta, V., Mircioiu, C., &Sandulovici, R. (2021). Analysis of the Variability of the Pharmacokinetics of the Long Half-Life Drug Amiodarone in Bioequivalence Studies. *Timisoara Med*, *2020*(2), 0-0.https://www.tmj.ro/article/2020/2/122

Leonenko, P., Ostanina, N., Kokoieva, Y., Levin, M., Leonenko, H., Gumeniuk, O., ... &Nikolaieva, Y. (2021). A survey and optical microscopy in pilot comparative analysis of generic and original nimesulide granules. *Heliyon*, *7*(7).https://www.cell.com/heliyon/pdf/S2405-8440(21)01593-0.pdf

Jeong, S. H., Jang, J. H., & Lee, Y. B. (2023). Population pharmacokinetic modeling of levodropropizine: Extended application to comparative analysis between commercial formulations and exploration of pharmacokinetic effects of diet. *Naunyn-Schmiedeberg's Archives of Pharmacology*, 1-16.https://link.springer.com/article/10.1007/s00210-023-02889-5

Naqvi, S. M. H., Gala, M. Y. N., Muchhala, S., Arumugam, A., Panigrahi, D., Patil, D., ... & Mane, A. (2023). Pharmacokinetics/Pharmacodynamics study of Fixtral SB as compared to supra bioavailable itraconazole and conventional itraconazole. *World Journal of Pharmacology*, *12*(1), 1-11.https://www.wjgnet.com/2220-3192/full/v12/i1/1.htm

Eremenko, N. N., &Goryachev, D. V. (2023). Selection of Adaptive Designs in Studies of Bioequivalence. Decision Criteria. *Pharmaceutical Chemistry Journal*, *57*(7), 1080-1088.https://link.springer.com/article/10.1007/s11094-023-02987-x

Patil, P. P., Pawar, A. P., Mahadik, K. R., & Gaikwad, V. L. (2021). An overview of regulations for bioequivalence assessment of locally acting orally inhaled drug products for the United States, Europe, Canada, and India. *Expert Opinion on Drug Delivery*, *18*(12), 1843-1855.https://www.tandfonline.com/doi/abs/10.1080/17425247.2021.2010701

Gao, P., Chen, J., Hong, Z., Choi, M., Morgan, A., Petushkov, A., ... & Reddy, B. Y. (2023). Landscape of cancer clinical trials in India–a comprehensive analysis of the Clinical Trial Registry-India. *The Lancet Regional Health-Southeast Asia*.https://www.thelancet.com/journals/lansea/article/PIIS2772-3682(23)00183-X/fulltext

Tellone, V., Picollo, R., Rosignoli, M. T., Garofolo, F., Del Vecchio, A., Calisti, F., ... &Wedemeyer, R. S. (2020). A novel rizatriptan oral gel formulation: Bioavailability and bioequivalence. *International Journal of Clinical Pharmacology and Therapeutics*, *58*(10), 583.https://search.proquest.com/openview/c292cfb9788d6f1d773efd608e897f77/1?pq-origsite=gscholar&cbl=2044854

Alwadi, A. Y., Arafeh, G. M., Almehlesi, M. S., Maswadeh, H. M., Salman, I. M., & Ameer, O. Z. (2022). Comparative Analysis of Commercially Available Acetaminophen Tablets in Saudi Arabia. *Dissolut. Technol*, *29*(3).https://www.researchgate.net/profile/Aiman-Alwadi-2/publication/363023735_Comparative_Analysis_of_Commercially_Available_Acetaminophen_Tablets_in_Saudi_Arabia/links/630a3c391ddd44702111eba1/Comparative-Analysis-of-Commercially-Available-Acetaminophen-Tablets-in-Saudi-Arabia.pdf?origin=journalDetail&_tp=eyJwYWdlIjoiam91cm5hbERldGFpbCJ9